Skip to content

Ironwood buy maintained by Cowen after 1Q miss

May 9, 2017

Cowen reiterated an Outperform rating and $20.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) following the company’s 1Q earnings report. IRWD reported US net sales of $147.6M in 1Q17 which was below the consensus estimates of $172.8M. The miss was driven by seasonality and differences in trade-buying patterns impacting drawdown in channel inventory.

Ironwood reiterated its expectation for IW-3718 GERD Phase 2b data in mid-2017 which represents the company’s next significant pipeline binary event. IW-3718 is a reformulation of a hypertension drug which is designed to sequester bile.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: